Montai will present data for the first time on its novel oral NRF2 agonist molecule, MTAI-1025, for ulcerative colitis (UC) ...
In patients with ischemic heart disease, myocardial ischemia–reperfusion injury (IRI) can aggravate their condition even worse, and diabetes increases their risk of myocardial IRI. Pathological ...
A new study identifies biliverdin reductase A (BVRA) as a crucial enzyme defending neurons from oxidative stress, acting ...
LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational New ...
Ra Pharmaceuticals Inc (NASDAQ:RARX) announced an agreement to be acquired by Belgian biopharma UCB for $48 per share in cash or $2.5 billion in total. The boards of both companies approved the ...
• Activation of nuclear factor erythroid 2-related factor 2 (Nrf2) significantly reduces the accumulation of senescent bronchial epithelial cells in chronic obstructive pulmonary disease (COPD) models ...
The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...
Non-alcoholic fatty liver disease (NAFLD) is characterized by an excessive accumulation of lipids in hepatocytes in non-alcoholic individuals. NAFLD progressively changes from fatty liver to ...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback